Digital technology aims to improve access to healthcare. However, for certain individuals with respiratory conditions, it may introduce additional barriers rather than eliminating existing ones.

This article aims to support healthcare professionals working within general practice to implement Ten ways to implement sustainable greener healthcare in primary care respiratory practice, a publication from the Primary Care Respiratory Society (PCRS). It offers practical tips, resources and advice on steps you can take to prioritise options and break down the activities required into manageable tasks. 

Are you passionate about respiratory care but frustrated by the pace of change? Do you have ideas about how things could be done better, but aren’t sure how to make your voice heard? The Primary Care Respiratory Society (PCRS) Respiratory Leaders Programme could be the catalyst you’ve been looking for.

CARRii’s inaugural annual scientific meeting brought together over 100 researchers, clinicians, innovators and patient partners from across the UK at a critical moment for the health service.

The UK Inhaler Group (UKIG) has produced a practical concise guide to support healthcare professionals in selecting and using spacer and valved holding chamber (VHC) devices for patients with asthma and COPD. Appropriate spacer/VHC selection and use can improve drug delivery, optimise disease control, and reduce treatment-related side effects. The guide highlights that selecting the right spacer matters just as much as choosing the right inhaler and that the best device is one a patient can and will use.

Asthma is a long term condition caused by inflammation of the airways leading to wheeze, cough, breathlessness and chest tightness. It is the most common chronic condition in childhood, affecting around 1.1 million children in the UK, equivalent to three children in every classroom. Many children with asthma also have atopy, meaning they are more likely to develop allergic conditions such as eczema or allergic rhinitis.

CARRii (Centre for Applied Respiratory Research & Innovation) is a UK research centre dedicated to enhancing lung health by supporting the implementation of high-quality research into clinical practice, with the aim of reducing hospital admissions, easing NHS winter healthcare pressures, and improving patient outcomes.

Anaphylaxis is a time-critical emergency. Prompt intramuscular (IM) adrenaline remains the first-line treatment, rapidly reversing airway oedema, vasodilatation and bronchospasm (MHRA, 2023). However, barriers such as fear of needles, incorrect injection technique or hesitancy are well documented and may delay or impair its administration. In real-world settings, these human factors can influence outcomes as much as the pharmacotherapy itself.

Allergic rhinitis (AR) is a common condition affecting between 15-25% of the general population; its symptoms significantly reduce quality of life and pose a high economic burden, including indirect costs related to lost school and workdays.